Nordsjaellands Hospital

nordsjaellandshospital.dk

Total trials

88

Active

25

Phase 3

3

Total enrollment

41,203

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 5 of 5 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Semaglutide Injectable Product1
Remifentanil1
Rocuronium1
Semaglutide 2.4mg1
Semaglutide placebo1

Next readouts

  • 2027-04-01
  • 2027-09
  • 2028-06

Top conditions

  • Postoperative Pain5
  • Community-acquired Pneumonia4
  • Pain3
  • Colles' Fracture3
  • Cesarean Section3
  • Abdomen, Acute3
  • Inflammatory Bowel Disease2
  • Pain, Postoperative2

Frequently asked questions about Nordsjaellands Hospital

How many clinical trials does Nordsjaellands Hospital have on ClinicalTrials.gov?
Nordsjaellands Hospital is listed as the lead sponsor on 88 clinical trials in ClinicalTrials.gov, 25 of which are currently active (recruiting, enrolling, or ongoing).
How many of Nordsjaellands Hospital's trials are in Phase 3?
3 of Nordsjaellands Hospital's trials are in Phase 3, spread across 5 active drug programs.
What therapeutic areas does Nordsjaellands Hospital focus on?
Nordsjaellands Hospital's most-studied conditions on ClinicalTrials.gov are Postoperative Pain, Community-acquired Pneumonia, Pain, Colles' Fracture, Cesarean Section.
When are Nordsjaellands Hospital's next clinical trial readouts?
Nordsjaellands Hospital has 3 upcoming primary-completion readouts tracked here; the soonest is “Remifentanil Versus Rocuronium for Optimizing Video Laryngoscopy-assisted Tracheal Intubation”, expected around 2027-04-01.